The market-implied odds of 89.5% against a new pandemic in 2026 reflect the continued absence of any novel pathogen achieving sustained human-to-human transmission capable of triggering widespread global outbreaks. As of mid-May, CDC and WHO surveillance data show only localized events, including limited Ebola Bundibugyo cases in Uganda and the Democratic Republic of the Congo plus seasonal respiratory viruses, with no emerging strain meeting official pandemic thresholds for rapid spread or high case-fatality impact. Ongoing monitoring of H5N1 avian influenza and mpox indicates zoonotic spillovers remain contained, while stalled WHO treaty talks highlight preparedness gaps without altering current low-risk conditions. Traders weigh this evidence against historical baselines of infrequent novel threats, though evolving variants or surveillance gaps could still shift trajectories before year-end.